Quick Answer
Coya Therapeutics, Inc. reported Cash and Equivalents of $46.82 million for fiscal year 2025.
Coya Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $46.82M | +22.1% |
| 2024 | $38.34M | +17.5% |
| 2023 | $32.63M | +449.9% |
| 2022 | $5.93M | +36.7% |
| 2021 | $4.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.13M | -9.4% | -5.5% |
| June 30, 2025 | $29.76M | -18.6% | -16.2% |
| March 31, 2025 | $35.53M | -1.3% | -7.3% |
| December 31, 2024 | $38.34M | +17.5% | +23.4% |
| September 30, 2024 | $31.06M | +185.3% | -15.1% |
| June 30, 2024 | $36.58M | +179.1% | +1.6% |
| March 31, 2024 | $35.99M | +120.5% | +10.3% |
| December 31, 2023 | $32.63M | +449.9% | +199.7% |
- Coya Therapeutics, Inc. showed an increase of +22.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Coya Therapeutics, Inc.’s cash and equivalents has grown by 978.8% (from $4.34 million to $46.82 million).
- The most recent figure is from Coya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: